Back to Journals » International Journal of Nanomedicine » Volume 10 » Issue 1

External beam radiotherapy synergizes 188Re-liposome against human esophageal cancer xenograft and modulates 188Re-liposome pharmacokinetics

Authors Chang CH, Liu SY, Chi CW, Yu HL, Chang TJ, Tsai TH, Lee TW, Chen YJ

Received 4 January 2015

Accepted for publication 18 March 2015

Published 19 May 2015 Volume 2015:10(1) Pages 3641—3649

DOI https://doi.org/10.2147/IJN.S80302

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Thomas J Webster

Chih-Hsien Chang,1,2 Shin-Yi Liu,3 Chih-Wen Chi,3 Hsiang-Lin Yu,1 Tsui-Jung Chang,1 Tung-Hu Tsai,4 Te-Wei Lee,1 Yu-Jen Chen3–5

1Isotope Application Division, Institute of Nuclear Energy Research, Taoyuan, Taiwan; 2Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, 3Department of Medical Research MacKay Memorial Hospital, 4Institute of Traditional Medicine, National Yang-Ming University, 5Department of Radiation Oncology, MacKay Memorial Hospital, Taipei, Taiwan

Abstract: External beam radiotherapy (EBRT) treats gross tumors and local microscopic diseases. Radionuclide therapy by radioisotopes can eradicate tumors systemically. Rhenium 188 (188Re)-liposome, a nanoparticle undergoing clinical trials, emits gamma rays for imaging validation and beta rays for therapy, with biodistribution profiles preferential to tumors. We designed a combinatory treatment and examined its effects on human esophageal cancer xenografts, a malignancy with potential treatment resistance and poor prognosis. Human esophageal cancer cell lines BE-3 (adenocarcinoma) and CE81T/VGH (squamous cell carcinoma) were implanted and compared. The radiochemical purity of 188Re-liposome exceeded 95%. Molecular imaging by NanoSPECT/CT showed that BE-3, but not CE81T/VGH, xenografts could uptake the 188Re-liposome. The combination of EBRT and 188Re-liposome inhibited tumor regrowth greater than each treatment alone, as the tumor growth inhibition rate was 30% with EBRT, 25% with 188Re-liposome, and 53% with the combination treatment at 21 days postinjection. Combinatory treatment had no additive adverse effects and significant biological toxicities on white blood cell counts, body weight, or liver and renal functions. EBRT significantly enhanced the excretion of 188Re-liposome into feces and urine. In conclusion, the combination of EBRT with 188Re-liposome might be a potential treatment modality for esophageal cancer.

Keywords: Radionuclide therapy, liposome, teletherapy, biodistribution

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Computer-aided classification of lung nodules on computed tomography images via deep learning technique

Hua KL, Hsu CH, Hidayati SC, Cheng WH, Chen YJ

OncoTargets and Therapy 2015, 8:2015-2022

Published Date: 4 August 2015

Modeling pegylated liposomal doxorubicin-induced hand-foot syndrome and intestinal mucositis in zebrafish

Chen YH, Lee YT, Wen CC, Chen YC, Chen YJ

OncoTargets and Therapy 2014, 7:1169-1175

Published Date: 1 July 2014

Integration of multidisciplinary technologies for real time target visualization and verification for radiotherapy

Chang WC, Chen CS, Tai HC, Liu CY, Chen YJ

OncoTargets and Therapy 2014, 7:1143-1150

Published Date: 23 June 2014

Readers of this article also read:

Monitoring cancer stem cells: insights into clinical oncology

Lin SC, Xu YC, Gan ZH, Han K, Hu HY, Yao Y, Huang MZ, Min DL

OncoTargets and Therapy 2016, 9:731-740

Published Date: 11 February 2016

Role of surface charge in determining the biological effects of CdSe/ZnS quantum dots

Liu QQ, Li HX, Xia QY, Liu Y, Xiao K

International Journal of Nanomedicine 2015, 10:7073-7088

Published Date: 16 November 2015

Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials

Van Heertum RL, Scarimbolo R, Ford R, Berdougo E, O’Neal M

Drug Design, Development and Therapy 2015, 9:5215-5223

Published Date: 11 September 2015

Prognostic role of apoptosis-related gene functional variants in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy

Tao KY, Li XX, Xu WZ, Wang Y, Zhu SM, Xie HX, Luo WH, Xu YJ, Xu XL

OncoTargets and Therapy 2015, 8:147-155

Published Date: 14 January 2015

Brachytherapy in the treatment of cervical cancer: a review

Banerjee R, Kamrava M

International Journal of Women's Health 2014, 6:555-564

Published Date: 28 May 2014

Multidisciplinary care in pediatric oncology

Cantrell MA, Ruble K

Journal of Multidisciplinary Healthcare 2011, 4:171-181

Published Date: 30 May 2011

Bevacizumab in the treatment of ovarian cancer

Ramez N Eskander, Leslie M Randall

Biologics: Targets and Therapy 2011, 5:1-5

Published Date: 11 January 2011

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010